BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug
May 11, 2016 at 10:25 AM EDT
* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.